PBLA vs. GRI, HSTO, NBSE, ATNF, INM, CMRA, SBFM, PRFX, GLMD, and BPTH
Should you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include GRI Bio (GRI), Histogen (HSTO), NeuBase Therapeutics (NBSE), 180 Life Sciences (ATNF), InMed Pharmaceuticals (INM), Comera Life Sciences (CMRA), Sunshine Biopharma (SBFM), PainReform (PRFX), Galmed Pharmaceuticals (GLMD), and Bio-Path (BPTH). These companies are all part of the "pharmaceutical preparations" industry.
GRI Bio (NASDAQ:GRI) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.
Panbela Therapeutics' return on equity of -795.54% beat GRI Bio's return on equity.
34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are owned by institutional investors. 16.8% of GRI Bio shares are owned by insiders. Comparatively, 0.0% of Panbela Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Panbela Therapeutics has a consensus price target of $500.00, indicating a potential upside of 113,536.36%. Given GRI Bio's higher probable upside, analysts clearly believe Panbela Therapeutics is more favorable than GRI Bio.
In the previous week, GRI Bio had 1 more articles in the media than Panbela Therapeutics. MarketBeat recorded 3 mentions for GRI Bio and 2 mentions for Panbela Therapeutics. Panbela Therapeutics' average media sentiment score of 0.15 beat GRI Bio's score of 0.00 indicating that GRI Bio is being referred to more favorably in the media.
GRI Bio is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks.
GRI Bio has a beta of -1.77, meaning that its share price is 277% less volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.
Panbela Therapeutics received 18 more outperform votes than GRI Bio when rated by MarketBeat users.
Summary
GRI Bio beats Panbela Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Panbela Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Panbela Therapeutics Competitors List
Related Companies and Tools
